Magnetic nanoparticles in MR imaging and drug delivery

被引:2119
作者
Sun, Conroy [1 ]
Lee, Jerry S. H. [2 ]
Zhang, Miqin [1 ]
机构
[1] Univ Washington, Dept Mat Sci & Engn, Seattle, WA 98195 USA
[2] NCI, Off Technol & Ind Relat, Bethesda, MD 20892 USA
关键词
magnetic nanoparticle; MRI; contrast agent; drug delivery; targeting; DNA; siRNA; peptide; ligand; cancer; biodistribution;
D O I
10.1016/j.addr.2008.03.018
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Magnetic nanoparticles (MNPs) possess unique magnetic properties and the ability to function at the cellular and molecular level of biological interactions making them an attractive platform as contrast agents for magnetic resonance imaging (MRI) and as carriers for drug delivery. Recent advances in nanotechnology have improved the ability to specifically tailor the features and properties of MNPs for these biomedical applications. To better address specific clinical needs, MNPs with higher magnetic moments, non-fouling surfaces, and increased functionalities are now being developed for applications in the detection, diagnosis, and treatment of malignant tumors, cardiovascular disease, and neurological disease. Through the incorporation of highly specific targeting agents and other functional ligands, such as fluorophores and permeation enhancers, the applicability and efficacy of these MNPs have greatly increased. This review provides a background on applications of MNPs as MR imaging contrast agents and as carriers for drug delivery and an overview of the recent developments in this area of research. (c) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:1252 / 1265
页数:14
相关论文
共 201 条
[91]  
Lubbe AS, 1996, CANCER RES, V56, P4686
[92]   Clinical applications of magnetic drug targeting [J].
Lübbe, AS ;
Alexiou, C ;
Bergemann, C .
JOURNAL OF SURGICAL RESEARCH, 2001, 95 (02) :200-206
[93]   Physiological aspects in magnetic drug-targeting [J].
Lübbe, AS ;
Bergemann, C ;
Brock, J ;
McClure, DG .
JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, 1999, 194 (1-3) :149-155
[94]   One-pot synthesis of PEGylated ultrasmall iron-oxide nanoparticles and their in vivo evaluation as magnetic resonance imaging contrast agents [J].
Lutz, Jean-Francois ;
Stiller, Sabrina ;
Hoth, Ann ;
Kaufner, Lutz ;
Pison, Ulrich ;
Cartier, Regis .
BIOMACROMOLECULES, 2006, 7 (11) :3132-3138
[95]   Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin [J].
Lyons, SA ;
O'Neal, J ;
Sontheimer, H .
GLIA, 2002, 39 (02) :162-173
[96]   Multifunctional nano-architecture for biomedical applications [J].
Ma, DL ;
Guan, JW ;
Normandin, F ;
Dénommée, S ;
Enright, G ;
Veres, T ;
Simard, B .
CHEMISTRY OF MATERIALS, 2006, 18 (07) :1920-1927
[97]   The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting [J].
Maeda, H .
ADVANCES IN ENZYME REGULATION, VOL 41, 2001, 41 :189-207
[98]   Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review [J].
Maeda, H ;
Wu, J ;
Sawa, T ;
Matsumura, Y ;
Hori, K .
JOURNAL OF CONTROLLED RELEASE, 2000, 65 (1-2) :271-284
[99]   Generation of superparamagnetic liposomes revealed as highly efficient MRI contrast agents for in vivo imaging [J].
Martina, MS ;
Fortin, JP ;
Ménager, C ;
Clément, O ;
Barratt, G ;
Grabielle-Madelmont, C ;
Gazeau, F ;
Cabuil, V ;
Lesieur, S .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2005, 127 (30) :10676-10685
[100]   A role for ion channels in glioxna cell invasion [J].
McFerrin, Michael B. ;
Sontheimer, Harald .
NEURON GLIA BIOLOGY, 2006, 2 :39-49